Business Context and Reporting Period
This Form 8-K was filed by OncoCyte Corporation (trading symbol: OCX) on April 23, 2020. The company develops cancer diagnostic tests, including DetermaRx, DetermaDx, and DetermaIO. The filing addresses liquidity measures taken in response to economic uncertainty related to the COVID-19 pandemic.
Key Financial Metrics and Obligations
- Debt: Entered into a Paycheck Protection Program (PPP) promissory note with Silicon Valley Bank for a principal amount of $1,140,930.
- Interest Rate: 1% per annum.
- Maturity Date: April 23, 2022.
- Payment Terms: Six-month deferral period with no payments due. Monthly principal and interest payments commence one month after the deferral period ends.
- Forgiveness: Principal is subject to forgiveness if proceeds are used for permitted expenses (payroll, rent, utilities), though no assurance of forgiveness is provided.
- Liquidity Measures: Implemented a compensation deferral program for executives and directors from May 2020 through December 2020. Deferred amounts accrue interest up to 10% per annum and may be settled in cash or common stock.
Material Changes
The filing reports the creation of a new direct financial obligation via the PPP loan. Additionally, the company has altered its cash flow management by deferring executive and director compensation to preserve liquidity. No revenue, profit, or margin figures are provided in this current report.
Guidance, Outlook, and Risks
Management states the PPP loan will help preserve jobs and support ongoing operations for cancer diagnostic test development and commercialization. The filing includes standard forward-looking statement disclaimers, noting that actual results may differ due to risks detailed in the company's most recent Form 10-K. There is no assurance that any portion of the PPP loan will be forgiven.
Investor Verification Checklist
- Verify the total amount of the PPP loan ($1,140,930) and its impact on the company's balance sheet.
- Confirm the specific terms of the executive compensation deferral, including the percentage of salaries deferred and the settlement method (cash vs. stock).
- Monitor future filings for updates on the status of the PPP loan forgiveness application.
- Review the company's most recent Form 10-K for detailed risk factors regarding the COVID-19 pandemic and product development timelines.